Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort

Journal of the American Academy of Dermatology
Shelley Ji Eun HwangPablo Fernandez-Peñas

Abstract

Anti-programmed cell death (PD)-1 therapy is emerging as the backbone of new standard of care immunotherapy for metastatic melanoma. Immune-related cutaneous events are observed in these patients. We sought to describe cutaneous adverse events observed in patients with metastatic melanoma on anti-PD-1 therapy. We reviewed the clinical and histologic information of all patients treated with single-agent anti-PD-1 therapy for metastatic melanoma at Westmead Hospital, Sydney, Australia, from May 2012 to February 2015. Of the 82 patients included in the study, 34 had dermatology assessments. Forty (49%) developed a form of anti-PD-1-associated cutaneous adverse events. In all, 17% developed lichenoid reactions and eczema, and 15% developed vitiligo. An estimated 25% of patients were expected to develop their first lichenoid reactions within 8.3 months, and eczema and vitiligo within 10.3 months of therapy. These adverse events tend to appear together in patients on anti-PD-1 therapy. The study was from a single center and clinical information was reviewed retrospectively in patients not referred to dermatology. Anti-PD-1 therapy is associated with the development of immune-related cutaneous events. Lichenoid reactions, eczema, and ...Continue Reading

References

Oct 18, 2005·Autoimmunity·Taku Okazaki, Jian Wang
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Jun 5, 2012·The New England Journal of Medicine·Julie R BrahmerJon M Wigginton
Nov 22, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Evan J LipsonSuzanne L Topalian
Dec 12, 2012·Expert Opinion on Investigational Drugs·Malgorzata Mackiewicz-WysockaPiotr J Wysocki
Feb 21, 2013·Expert Opinion on Biological Therapy·Omid Hamid, Richard D Carvajal
Jun 4, 2013·The New England Journal of Medicine·Omid HamidAntoni Ribas
Sep 14, 2013·Critical Reviews in Oncology/hematology·Barbara MerelliMario Mandalà
Mar 13, 2014·Archives of Dermatological Research·Andrew MamalisJared Jagdeo
May 14, 2014·Oral Oncology·Dan P Zandberg, Scott E Strome
Oct 8, 2014·Cancer Immunology Research·Richard W JosephAnokhi Jambusaria-Pahlajani
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Mar 10, 2015·Molecular Immunology·Abhisek SwaikaRichard W Joseph
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
May 2, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ryan J Sullivan, Keith T Flaherty
Jun 2, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Jul 30, 2015·JAMA Dermatology·Martina SanlorenzoSusana Ortiz-Urda
Oct 9, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Morganna Freeman-KellerJeffrey Weber

❮ Previous
Next ❯

Citations

Mar 22, 2016·Expert Review of Anticancer Therapy·Nora WoltscheIris Zalaudek
Aug 10, 2016·JAAD Case Reports·Jonathan CotliarRobert Chen
Sep 20, 2016·Actas dermo-sifiliográficas·S J E HwangP Fernandez-Peñas
Oct 26, 2016·Expert Review of Anticancer Therapy·Pol Specenier
Nov 20, 2016·Journal of Cutaneous Pathology·Jonathan L CurryVictor G Prieto
Feb 22, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·J P BandinoD M Elston
Jan 31, 2017·The American Journal of Dermatopathology·Michael T TetzlaffJonathan L Curry
Mar 23, 2017·Expert Opinion on Biological Therapy·Pol Specenier
Mar 16, 2017·The Journal of Dermatology·Hajime MiyazawaHiroshi Shimizu
Jul 15, 2017·The Australasian Journal of Dermatology·Cathy Yunjia ZhaoPablo Fernández-Peñas
Jul 21, 2017·The Australasian Journal of Dermatology·Rose C LiuPatricia M Lowe
Dec 10, 2017·Clinical and Experimental Dermatology·J DennyV Akhras
Mar 22, 2018·Expert Review of Anticancer Therapy·Pol Specenier
Mar 23, 2018·Cellular & Molecular Immunology·Hannah M KnochelmannChrystal M Paulos
Nov 9, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·S ThomasH Schaider
Jun 14, 2018·The Australasian Journal of Dermatology·Mayuri TanakaHidehisa Saeki
Jun 20, 2018·Clinical and Experimental Dermatology·G BioloM Alaibac
Jun 26, 2018·Journal of Cutaneous Pathology·Robert J SmithEmily Y Chu
Apr 19, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·V SibaudM E Lacouture
Aug 2, 2018·Current Oncology Reports·David J Palmieri, Matteo S Carlino
Sep 1, 2018·Melanoma Research·Cathy Yunjia ZhaoPablo Fernandez-Peñas
Jan 9, 2019·Clinical and Experimental Dermatology·R C LiuP Fernandez Peñas
Jan 27, 2018·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·H F MerkM Megahed
Feb 28, 2019·International Journal of Dermatology·Elisa CinottiPietro Rubegni
Apr 5, 2019·Immunotherapy·Tarek AssiVincent Ribrag
Jul 31, 2018·Current Drug Safety·Kerasia-Maria PlachouriSophia Georgiou
Jan 18, 2019·Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Società Italiana Di Dermatologia E Sifilografia·Léa DoussetJulien Seneschal
Dec 20, 2017·American Journal of Clinical Dermatology·Vincent Sibaud
Jan 18, 2018·The British Journal of Surgery·P M FergusonJ F Thompson
Sep 27, 2019·Cancers·Malgorzata BobrowiczMagdalena Winiarska
Oct 30, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·M FässlerL Borradori
Aug 18, 2017·The American Journal of Surgical Pathology·Genevieve J KaunitzJanis M Taube
Mar 25, 2020·Journal of Investigative Medicine High Impact Case Reports·Ivy RianoThomas Treadwell
Mar 29, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Vasiliki NikolaouA Stratigos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis